Supernus and Indivior Agree to Merge, Creating $2.2 Billion CNS Biopharma Leader
Supernus and Indivior merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility.
/ 1 item
#SUPN↓